Sun Pharma Q3 results: Sun Pharmaceutical Industries is set to release its Q3 results, with expected mode ...More

Sun Pharma Q3 results: Sun Pharmaceutical Industries is set to release its Q3 results, with expected moderate earnings growth. Analysts will monitor factors including US business growth, Taro Pharmaceutical's performance, margin trajectory, planned product launches, and R&D investments. Estimated growth in net profit, revenue, and operating profit is also anticipated. The company is expected to see a rise in US revenue, driven by specialty sales. Growth in domestic formulations is projected, and R&D spend will be closely monitored. ...Less

Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global special ...More

Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global specialty sales. Revenue grew 10.5%, while EBITDA surged 15.3% with improved margins. The company faces ongoing legal proceedings in the U.S. ...Less

Kotak Securities expects 16.4 per cent drop in profit at Rs 1,036.50 crore. ...More

Kotak Securities expects 16.4 per cent drop in profit at Rs 1,036.50 crore. ...Less

Sun Pharma Q3 Results: The company has also declared an interim dividend of Rs 10.5 per share for the fin ...More

Sun Pharma Q3 Results: The company has also declared an interim dividend of Rs 10.5 per share for the financial year 2024-25. ...Less

Sun Pharma posted a strong Q3FY26 performance with net profit up 16% and revenue rising 13%. EBITDA surge ...More

Sun Pharma posted a strong Q3FY26 performance with net profit up 16% and revenue rising 13%. EBITDA surged 23% as margins expanded to 31.9%. Growth was broad-based across India, emerging markets and RoW, while the US business remained steady. The company also declared an interim dividend of Rs 11 per share. ...Less

Sun Pharmaceutical Industries Ltd is expected to report single-digit revenue growth for Q3 earnings, with ...More

Sun Pharmaceutical Industries Ltd is expected to report single-digit revenue growth for Q3 earnings, with moderate sales in the US and India. Analysts predict a nearly 8% YoY growth in consolidated net profit to Rs 2,329 crore. Consolidated revenue is estimated to rise 9% YoY to Rs 12,265.40 crore. ...Less

The company had reported consolidated profit of Rs 1,471.82 crore in the corresponding quarter of last ye ...More

The company had reported consolidated profit of Rs 1,471.82 crore in the corresponding quarter of last year. ...Less

The earnings before interest, tax, depreciation and ammortisation (EBITDA) grew 15.2% YoY to Rs. 3004 cro ...More

The earnings before interest, tax, depreciation and ammortisation (EBITDA) grew 15.2% YoY to Rs. 3004 crore. The EBITDA margin for Q3FY23 improved 30 basis points YoY to 26.7%.Global specialty drug sales were at $235 million, including US$12.5 million milestone received in Q3FY23. Ex-milestone, the specialty sales were up 21.6% YoY in Q3FY23. ...Less

Revenue from operations during the quarter rose 14% to Rs 11,240 crore against Rs 9,863 crore in the corr ...More

Revenue from operations during the quarter rose 14% to Rs 11,240 crore against Rs 9,863 crore in the corresponding quarter of the previous year. ...Less

According to an ETNow poll, the drugmaker’s consolidated revenue for the quarter ended December is seen r ...More

According to an ETNow poll, the drugmaker’s consolidated revenue for the quarter ended December is seen rising 12.5% on-year to Rs 11,100 crore ...Less

Here are the top takeaways from Sun Pharma’s third-quarter earnings. ...More

Here are the top takeaways from Sun Pharma’s third-quarter earnings. ...Less

The total revenue from operations came in at Rs 9,863.06 crore, up 11.61 per cent against Rs 8,836.78 cro ...More

The total revenue from operations came in at Rs 9,863.06 crore, up 11.61 per cent against Rs 8,836.78 crore in the corresponding quarter last year. ...Less

Sun Pharmaceuticals and Maruti Suzuki India are among the companies declaring their Q3FY24 earnings. Maru ...More

Sun Pharmaceuticals and Maruti Suzuki India are among the companies declaring their Q3FY24 earnings. Maruti Suzuki India is expected to report healthy revenue growth, while Sun Pharmaceuticals may see moderate revenue growth. ...Less

Sun Pharmaceutical Industries reported a 17.4% YoY growth in net profit for Q4, beating estimates. Consol ...More

Sun Pharmaceutical Industries reported a 17.4% YoY growth in net profit for Q4, beating estimates. Consolidated revenue grew 10% YoY. The company recommended an interim dividend payout. EBITDA rose 16% YoY and margins expanded. Raw material cost fell, but staff cost increased. India formulation sales and US formulation sales grew, while emerging markets formulation sales declined. ...Less

The stock was trading with minor gains at the opening time and hit the day's high of Rs 1,430.45 on the N ...More

The stock was trading with minor gains at the opening time and hit the day's high of Rs 1,430.45 on the NSE, up 0.84% over the Wednesday closing price. ...Less

The company had reported Rs 321.57 crore profit in the same quarter last year. ...More

The company had reported Rs 321.57 crore profit in the same quarter last year. ...Less

Taro Pharma reported a 422 per cent year-on-year (YoY) jump in its net profit for the third quarter. ...More

Taro Pharma reported a 422 per cent year-on-year (YoY) jump in its net profit for the third quarter. ...Less

Sun Pharma reported a 15% YoY rise in Q3FY25 profit to Rs 2,903 crore, surpassing estimates. Revenue grew ...More

Sun Pharma reported a 15% YoY rise in Q3FY25 profit to Rs 2,903 crore, surpassing estimates. Revenue grew 10% to Rs 13,675.5 crore, driven by domestic and emerging markets. API sales rose 22%, while formulation sales in the US slightly declined. Nuvama maintained a 'Hold' rating with a target price of Rs 1,830, citing strong emerging market performance and R&D uncertainty. ...Less

Ebitda margins to remain steady QoQ, at 22 per cent, Edelweiss said. ...More

Ebitda margins to remain steady QoQ, at 22 per cent, Edelweiss said. ...Less

Sun Pharma shares rose sharply on Sunday after the company reported a 16% YoY rise in Q3 net profit to Rs ...More

Sun Pharma shares rose sharply on Sunday after the company reported a 16% YoY rise in Q3 net profit to Rs 3,369 crore, supported by strong India business and improved margins. The firm also declared an interim dividend of Rs 11 per share, further boosting sentiment despite cautious institutional activity. ...Less

Sun Pharma announced strong third quarter results. Sales rose 15% to Rs 15,469 crore and net profit climb ...More

Sun Pharma announced strong third quarter results. Sales rose 15% to Rs 15,469 crore and net profit climbed 16% to Rs 3,368 crore. Growth was fueled by its branded businesses in India and emerging markets, along with global innovative medicines. The company also declared an interim dividend. ...Less

Sun Pharma on Wednesday reported a 16.5% year-on-year (YoY) jump in net profit to Rs 2524 crore in Q3FY24 ...More

Sun Pharma on Wednesday reported a 16.5% year-on-year (YoY) jump in net profit to Rs 2524 crore in Q3FY24 led by broad-based growth, including higher sales of global specialty products. ...Less

Margin fell to 22.6 per cent compared with 27.8 per cent in the same quarter last year. ...More

Margin fell to 22.6 per cent compared with 27.8 per cent in the same quarter last year. ...Less

The company intends to increase its specialty drug portfolio in its core areas of dermatology and ophthal ...More

The company intends to increase its specialty drug portfolio in its core areas of dermatology and ophthalmology. This comes at a time when the company’s generic business continues to face pricing pressure. The company’s Halol plant, receiving an import alert from the USFDA earlier in December, remains a challenge for Sun. ...Less

Net sales for the pharma major is seen rising 9.04 per cent YoY to Rs 9,635 crore from Rs 8,836 crore in ...More

Net sales for the pharma major is seen rising 9.04 per cent YoY to Rs 9,635 crore from Rs 8,836 crore in the same quarter last year. Ebitda could climb to Rs 2,486 crore from Rs 2,406 crore in the year-ago quarter, the ET NOW poll suggested. ...Less

Sun Pharma reported a 28% year-on-year (YoY) jump in net profit to Rs 3040 crore in Q2FY25 led by higher ...More

Sun Pharma reported a 28% year-on-year (YoY) jump in net profit to Rs 3040 crore in Q2FY25 led by higher sales growth in domestic formulation and global specialty portfolio. ...Less

Other income for the quarter surged to Rs 314.95 crore compared with Rs 119.88 crore in the year-ago quar ...More

Other income for the quarter surged to Rs 314.95 crore compared with Rs 119.88 crore in the year-ago quarter. ...Less

Sun Pharmaceutical Industries reported a net profit of Rs 3,117.95 crore for Q2 FY26, a 2.6% year-on-year ...More

Sun Pharmaceutical Industries reported a net profit of Rs 3,117.95 crore for Q2 FY26, a 2.6% year-on-year increase. Revenue from operations grew 8.6% to Rs 14,405.22 crore, with U.S. Innovative Medicines sales surpassing Generics for the first time. The company's R&D investment stood at 5.4% of sales. ...Less

Sun Pharmaceutical Q2 FY25 Results: Sun Pharma reported a 28% increase in consolidated net profit for Q2, ...More

Sun Pharmaceutical Q2 FY25 Results: Sun Pharma reported a 28% increase in consolidated net profit for Q2, reaching Rs 3,040 crore, up from Rs 2,375 crore last year. Revenue rose 9% YoY to Rs 13,291 crore, surpassing market estimates. EBITDA grew 24% YoY to Rs 3,939 crore, with a margin of 29.6%. Formulation sales in India increased 11% YoY to Rs 4,265 crore, representing 32% of total sales. ...Less

IDFC First Bank posted a strong Q3FY26 performance with net profit rising 48% to Rs 503 crore and NII up ...More

IDFC First Bank posted a strong Q3FY26 performance with net profit rising 48% to Rs 503 crore and NII up 12% year-on-year. Asset quality improved with lower gross NPAs, while loan growth remained broad-based. The bank saw steady momentum in credit cards and wealth management, supported by easing provisions. ...Less

Results that will be out on January 30 include Larsen & Toubro, Bajaj Finserv, Tech Mahindra, Bharat Petr ...More

Results that will be out on January 30 include Larsen & Toubro, Bajaj Finserv, Tech Mahindra, Bharat Petroleum Corporation, Bajaj Holdings & Investment, GAIL, SRF, Punjab National Bank, REC, Laurus Labs, IIFL Finance, Trident, Exide Industries, Nippon Life India Asset Management, Mazagon Dock Shipbuilders, Welspun as well as Inox Leisure. ...Less

Barring Taro, no major momentum registered by Sun's business in the US was concerning. Existing product r ...More

Barring Taro, no major momentum registered by Sun's business in the US was concerning. Existing product range in the US fell below the expectation. ...Less

Barring Taro, no major momentum registered by Sun's business in the US was concerning. Existing product r ...More

Barring Taro, no major momentum registered by Sun's business in the US was concerning. Existing product range in the US fell below the expectation. ...Less

Sun Pharma Q1 Results FY26: Sun Pharmaceutical Industries reported a 20% fall in Q1 consolidated net prof ...More

Sun Pharma Q1 Results FY26: Sun Pharmaceutical Industries reported a 20% fall in Q1 consolidated net profit, reaching Rs 2,278 crore. Despite this dip, revenue from operations increased by 10% to Rs 13,786 crore. Strong performance in the India market and growth in global innovative medicines sales, including the U.S. launch of LEQSELVI, contributed to the company's overall progress. ...Less

Adani Enterprises Q1 Results FY26: Adani Enterprises experienced a 45% profit drop in the first quarter, ...More

Adani Enterprises Q1 Results FY26: Adani Enterprises experienced a 45% profit drop in the first quarter, reaching Rs 976.48 crore. Revenue also decreased by 13.7% to Rs 21,961.20 crore. Lower trade volumes and index price volatility impacted performance. However, incubating businesses saw a 5% EBITDA increase, driven by Airports and Roads segments. Navi Mumbai Airport and other projects are expected to contribute to future EBITDA. ...Less

Bharti Airtel Q2 Results: The company's revenue from operations for the quarter reached Rs 41,473 crore, ...More

Bharti Airtel Q2 Results: The company's revenue from operations for the quarter reached Rs 41,473 crore, marking a 12% increase from Rs 37,044 crore in the same quarter last year. The average revenue per user (ARPU) rose 15% year-on-year to Rs 233 from Rs 203 in Q2FY24. Consolidated net income (before exceptional items) increased by 32.2% YoY to Rs 3,911 crore. ...Less

ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun ...More

ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC's revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma. ...Less

Revenue from operations is likely to jump 10% year-on-year, according to the average estimate of four bro ...More

Revenue from operations is likely to jump 10% year-on-year, according to the average estimate of four brokerages. Meanwhile, net profit for the quarter is projected to rise by up to 25% YoY. The pharma major will report its September quarter results on Monday, October 28. ...Less

The S&P BSE Sensex rallied as much as 355 points in intraday trade on Tuesday led by gains in auto, capit ...More

The S&P BSE Sensex rallied as much as 355 points in intraday trade on Tuesday led by gains in auto, capital goods and oil & gas sectors. ...Less

The S&P BSE Sensex rallied nearly 400 points in intraday trade on Tuesday led by gains in auto, capital g ...More

The S&P BSE Sensex rallied nearly 400 points in intraday trade on Tuesday led by gains in auto, capital goods and oil & gas sectors. ...Less

The S&P BSE Sensex rallied as much as 266 points in intraday trade on Tuesday led by gains in auto, capit ...More

The S&P BSE Sensex rallied as much as 266 points in intraday trade on Tuesday led by gains in auto, capital goods and oil & gas sectors. ...Less